Transcatheter Aortic Valve Replacement (TAVR)

The transcatheter aortic valve replacement (TAVR) is a promising new treatment for patients with severe aortic stenosis (narrowing of the heart valve) who are not ideal candidates for traditional open heart surgery.The Hospital of the University of Pennsylvania (HUP) is one of 23 hospitals nationwide that are participating in the FDA regulated clinical trial examining the use of this minimally invasive procedure as part of a clinical trial (PARTNER Trial). HUP successfully performed its first TAVR procedure in November 2007. The co-principal investigators for this trial at the University of Pennsylvania are Joseph E. Bavaria, MD, director of the Thoracic Aortic Surgery Program and Howard C. Herrmann, MD, director of the Interventional Cardiology and Cardiac Catheterization Laboratories.


April 22, 2013

Created by

Penn Physician VideoLink